SARS-CoV-2

[Cancer Cell] Using a prospective cohort, reseearchers assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the 1st and 2nd dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in U.S. and Europe from January to April 2021.

[Cell] Scientists isolated neutralizing antibodies against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection.

[Cell Host & Microbe] Scientists investigated the capacity of modified versions of one lead miniprotein, LCB1, to protect against SARS-CoV-2-mediated lung disease in mice.

[Science Advances] Investigators demonstrated that protein kinase R–like endoplasmic reticulum kinase (PERK) signaling mediated the proapoptotic signals in Middle East respiratory syndrome coronavirus (MERS-CoV) infection, which converged in the intrinsic apoptosis pathway.

[Nature Communications] Scientists longitudinally profiled the early humoral immune response against SARS-CoV-2 in hospitalized coronavirus disease 2019 (COVID-19) patients and quantify levels of pre-existing immunity to OC43, HKU1 and 229E seasonal coronaviruses

[Nature Nanotechnology] Scientists showed that ACE2 nanodecoys derived from human lung spheroid cells could bind and neutralize SARS-CoV-2 and protect the host lung cells from infection.